0.16 /LM) in RPMI 1640 culture medium (8.3 mM-glucose, 0.43 mM-Ca2") abolished TPA (0.16 /,M)-induced insulin secretion and led to a potentiation of phase 1 and a decrease in phase 2 of glucose-induced insulin secretion. Thus, although the total insulin release during 40 min of perifusion with glucose (16.7 mM) (45-85 min) was unaffected, the percentage released during phase 1 (45-55 min) was increased from 12.9 + 1.5 (4) o in controls to 35.8 + 3.9 (4)% in TPA-treated islets (P < 0.01), and the percentage released during phase 2 (65-85 min) was decreased from 63.2 + 3.9 (4)% to 35.3 + 1.4 (4)% (P < 0.005). In contrast, TPA exposure in TCM 199 medium (5.5 mM-glucose, 1.26 mM-Ca2+) caused a total abolition of both phases 1 and 2 of glucose-induced secretion. However, inclusion of the a2-adrenergic agonists adrenaline (10 ,UM) or clonidine (10 /LM), or lowering of the Ca2+ concentration in TCM 199 during down-regulation, preserved and potentiated phase 1 of glucose-induced secretion. Furthermore, perifusion of islets in the presence of staurosporine (1 /tM), an inhibitor of protein kinase C, potentiated phase 1 and inhibited phase 2 of glucoseinduced secretion. In addition, down-regulation of protein kinase C potentiated phase I and inhibited phase 2 of carbamoylcholine (100 /M)-induced insulin secretion at 3.3 mM-glucose, and abolished the potentiating effect of carbamoylcholine (100 #sM) at 16.7 mM-glucose. These results substantiate a role for protein kinase C in insulin secretion, and suggest that protein kinase C inhibits phase 1 and stimulates phase 2 of both glucose-induced and carbamoylcholine-induced insulin secretion.
INTRODUCTION
Recent evidence suggests that glucose-induced insulin secretion from the pancreatic fl-cell may be controlled by three convergent and interdependent regulatory pathways involving changes in the cytosolic Ca21 concentration and intracellular concentrations of cyclic AMP and diacylglycerol (Prentki & Matschinsky, 1987) . The transduction of these signals is believed to occur through activation of Ca2+/calmodulin-dependent protein kinase, cyclic AMP-dependent protein kinase and protein kinase C. Although it is widely recognized that glucose-stimulated insulin secretion is dependent on Ca2+ mobilization and that glucose-stimulated cyclic AMP accumulation potentiates Ca2+-induced secretion, the role of protein kinase C in glucose-induced secretion is still debated. Glucose has been demonstrated to stimulate diacylglycerol formation in rat islets (Peter-Riesch et al., 1988) and to induce protein kinase C-mediated protein phosphorylation in neonatal islets (Dunlop & Larkins, 1986) . Furthermore, we have recently found evidence to suggest that glucose-induced cyclic AMP formation in mouse islets is mediated by protein kinase C . However, other data have cast doubt on the significance of protein kinase C in glucose-induced secretion. Down-regulation of protein kinase C, which may be observed after prolonged exposure to TPA, was found to be without effect on glucose-induced secretion in rat islets (Hii et al., 1987; Metz, 1988) . Furthermore, several inhibitors of protein kinase C have been shown to be rather poor inhibitors of glucose-induced secretion. Thus, clomiphene was shown to cause a selective inhibition of TPA-induced insulin secretion (Hughes & Ashcroft, 1988) , and H-7 was found to abolish TPAinduced and carbamoylcholine-induced insulin secretion while leaving glucose-induced secretion almost unaffected (Malaisse & Sener, 1985) . However, these results were all obtained in static incubations, comprising both phases 1 and 2 of glucose-induced secretion.
In seeking an explanation for these discrepancies, the present study aimed to investigate the effects of downregulation of protein kinase C on the dynamics of insulin secretion in mouse islets. The results substantiate a role for protein kinase C in glucose-induced insulin secretion and suggest that protein kinase C may inhibit phase 1 and stimulate phase 2 of glucose-induced secretion.
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Abbreviations used: TPA, 12-0-tetradecanoylphorbol 13-acetate; 4ac-PDD, 4a-phorbol 12,13-didecanoate; H-7, 1-(5-isoquinolinylsulphonyl)-2-methylpiperazine.
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P. Thams and others EXPERIMENTAL Materials
Crude bacterial collagenase and staurosporine were obtained from Boehringer, Mannheim, Germany. Tes, Hepes, EGTA, dithiothreitol, phosphatidylserine, 40c-PDD, TPA, -carbamoylcholine chloride, adrenaline and clonidine were purchased from Sigma Chemical Co., St. Louis, MO, U.S.A. Human serum albumin was from Behringswerke A.G., Marburg, Germany. [y-32P]ATP (sp. radioactivity 3000 Ci/mmol) was from Amersham International, Amersham, Bucks., U.K. '25I-insulin and guinea-pig anti-insulin serum were kindly provided by Nordisk Gentofte A/S, Gentofte, Denmark. All other chemicals were of analytical grade.
Preparation of islets
Islets were prepared by collagenase digestion of the pancreases of male albino mice (NMRI) (approx. 18-22 g body wt.) fed ad libitum on a standard laboratory diet. Islets were kept in tissue culture for 22-24 h in TCM 199 medium (1.26 mM-Ca2", 5.5 mM-glucose) or RPMI 1640 medium (0.43 mM-Ca2", 8.3 mM-glucose) supplemented with 100% (v/v) newborn-calf serum (Gibco), 20 mM-Hepes, 5 mM-NaHCO3, 100 units of penicillin/ml, 100 ,ug of streptomycin/ml and further additions where indicated.
Phosphorylation assay
Groups of 50 mouse islets were collected in 200 ,l of 25 mM-Tes buffer, pH 6.90, containing 5 mM-MgCl2, 1 mM-EGTA, 0.1 mM-dithiothreitol, 0.01 0% (w/v) Insulin release from islets was measured by perifusion in a non-circulating system with beads of polyacrylamide as a supporting medium, essentially as described by Knudsen et al. (1983) . The present device allowed the simultaneous perifusion of six columns. In each experiment 25 islets were added on top of a column consisting of 0.25 ml of Bio-Gel P-2 (Bio-Rad Laboratories, Rockville Center, NY, U.S.A.) and carefully mixed with the beads. The islets were perifused at 37°C at a flow rate of 0.26 ml/min. The perifusion medium was Krebs-Ringer medium supplemented with 20 mM-Hepes, 5 mM-NaHCO3, 2 mg of human serum albumin/ml and 3.3 mM-glucose. Islets were perifused for 45 min with 3.3 mm-glucose to obtain a basal release rate and then challenged with different insulin secretagogues and test agents as indicated in the Figures and Tables. The effluent medium was collected for periods of 5 or 10 min and stored at -20°C until assayed for insulin content. The rate of insulin release was expressed as ng of insulin/min per 100 islets. Islet insulin content Groups of 10 islets were collected in 1 ml of 0.7 MHCl/ethanol (1: 3, v/v) and incubated for approx. 20 h at 4°C for extraction of insulin (Trimble & Renold, 1981) .
Insulin assay
Insulin was determined by radioimmunoassay using a guinea-pig anti-insulin serum, monoiodinated pig insulin as tracer, rat insulin as standard, and ethanol to separate antibody-bound from free insulin. Miscellaneous 4cx-PDD, TPA and staurosporine were added in a small volume of dimethyl sulphoxide, final concn.
0.01 0.1% (V/V) Results are given as means + S.E.M. for n experiments. Statistical evaluation of the data was made by Student's paired t test; NS, not significant (P > 0.05).
RESULTS
Effects of TPA pre-exposure on glucose-induced and TPA-induced insulin secretion Fig. 1 shows the dynamics of insulin release from column-perifused mouse islets in response to glucose (16.7 mM) and TPA (0.16,tM). Islets were cultured for 22-24 h in TCM 199 culture medium containing 5.5 mMglucose and 1.26 mM-Ca2l (Fig. la) or in RPMI 1640 culture medium containing 8.3 mM-glucose and 0.43 mMCa2l (Fig. lb) . In control islets from both media, stimulation by glucose (16.7 mM) was characterized by a dominant phase 2 of secretion and a smaller non-distinct phase 1 of secretion (45-55 min (Tables 1 and 2 ). Furthermore, adrenaline (10 UtM) did not prevent down-regulation of TPA-inducible secretion during TPA exposure in TCM 199 medium (Fig. 2a) . Similar results were obtained with clonidine (10 /tM), a specific ac2-adrenergic agonist (Fig.  2b) . Thus, although the total insulin release during 45-85 min of perifusion with glucose (16.7 mM) was unaffected after exposure to TPA in the presence of either adrenaline or clonidine (Table 1) , down-regulation caused a shift in the time course of glucose-induced secretion ( Table 2) . Effect of TPA pre-exposure on carbamoylcholineinduced insulin secretion Fig. 3(a) shows the time course of carbamoylcholineinduced insulin secretion from islets after culture in TCM 199 medium. At 3.3 mM-glucose, carbamoylcholine (100 /uM) elicited a biphasic response, consisting of a dominant phase 1 (45-55 min) and a small phase 2 (65-85 min) of secretion. At 16.7 mM-glucose, carbamoylcholine (100 ,/M) caused a persistent potentiation of glucoseinduced secretion (185-235 min) (Fig. 3a) . All responses to carbamoylcholine were abolished in TPA-pretreated islets (Fig. 3a) . Inclusion of adrenaline (10 /tM) in TCM 199 during TPA exposure, however, retained and potentiated the ability of carbamoylcholine at 3.3 mM-glucose to induce phase 1 of secretion (Fig. 3b) . Thus, although the total insulin released during 40 min of perifusion with carbamoylcholine (100 /LM) (45-85 min) was unaffected (Table 3) , the percentage released during phase 1 (45-55 min) was increased from 36.2 + 4.1 (4) o in adrenalinepretreated islets to 78.2 + 8.2 (4) o in adrenaline + TPApretreated islets (P < 0.005), and the percentage released during phase 2 (65-85 min) was decreased from 44.9 + 4.0 (4)%/ to 11.8 + 4.0(4)%O (P < 0.005) ( Table 4 ). Adrenaline (10 /uM) itself did not affect total insulin release (Table 3) , but tended to show a slight effect on the time course, increasing the fractional output during phase 2 of secretion (Table 4) .
In line with an inhibitory effect of down-regulation of protein kinase C on phase 2 of carbamoylcholineinduced secretion at 3.3 mM-glucose, pretreatment with adrenaline + TPA abolished the potentiating effect of carbamoylcholine at 16.7 mM-glucose (185-235 min) (Fig. 3b, Table 3 ).
Vol. 265 (Fig. 4) . In comparison, exposure to the inactive phorbol ester 4a-PDD did not affect protein kinase C activity. Complete down-regulation of protein kinase C in response to TPA was not achieved. Prolonged exposure for 48 h to TPA (0.16 ,IM), which was a maximum stimulating concentration, appeared to cause a total abolition of activity, but was associated with a cell loss of approx. 5000 (results not shown).
Neither adrenaline (10 ,uM) nor clonidine (10 /tM) influenced protein kinase C itself or affected TPA-induced down-regulation of protein kinase C (Fig. 4) (Table 5 ). In addition, inclusion of EGTA (1 mM) in TCM 199 showed no effect on insulin content in the absence or presence of TPA (Table 5) . The ability of a2-adrenergic agonists to preserve and potentiate phase 1 of glucose-induced secretion in TPAexposed islets (Fig. 2 ) may rely on an inhibitory effect of these agents on Ca2l uptake (Wollheim et al., 1977) or on distal steps in Ca2l-induced secretion (Tamagawa et al., 1985; Jones et al., 1987) during down-regulation in TCM 199 medium. Furthermore, the observed difference (Tables 1 and 2 ). In line with the above considerations, however, EGTA (1 mM) in combination with TPA led to preservation and potentiation of phase 1 (45-55 min) of glucose-induced insulin secretion, but decreased phase 2 (65-85 min) of glucose-induced secretion and abolished TPA-induced (105-165 min) secretion (Fig. 5) . Thus, although total insulin release with glucose (16.7 mM) (45-85 min) was unchanged (Table 1) , the fractional release during phase 1 (45-55 min) was enhanced from 20.9 + 2.4 (3)o% in EGTA-exposed islets to 37.0+3.4 (3)% in EGTA+TPA-exposed islets (P< 0.005), and the fractional release during phase 2 was decreased from 56.5+ 1.7 (3) % to 39.7 +4.3 (3) O (Table 2 ).
In addition to Ca2+, the concentration of glucose in the media was critical. An increase in glucose from 8.3 mm to the conventional 11 mM in RPMI 1640 during TPA exposure led to abolition of both phases of glucoseinduced secretion in subsequent perifusion experiments (results not shown). Effect of staurosporine on insulin secretion
To substantiate further a role for protein kinase C in glucose-induced insulin secretion, the effect of staurosporine, an inhibitor of protein kinase C (Tamaoki et al., 1986) , was investigated. Staurosporine (1 /LM) caused total abolition of TPA-stimulated release (105-165 min) (Fig. 6 ). This inhibition of TPA-induced secretion was associated with a potentiation of phase 1 and a decrease in phase 2 of glucose-induced secretion. Thus the percentage released during phase 1 (45-55 min) was increased from 14.0 + 1.6(3)% in controls to 35.7 + 4.8 (3) % in staurosporine-perifused islets (P < 0.02), and the percentage released during phase 2 was decreased from 61.0+ 3.6 (3)% to 34.4+ 6.0 (3)% (P < 0.05) ( Staurosporine (1 JIM) was without effect on both basal release at 3.3 mM-glucose (15-45 min) and the total amount of insulin released during 40 min of perifusion with 16.7 mM-glucose (45-85 min) ( Table 1) .
Comparative studies with rat islets In previous studies with rat islets, an abolishing effect ofTPA pretreatment on glucose-induced insulin secretion was not observed (Hii et al., 1987; Metz, 1988) . In view of this apparent discrepancy with our results with mouse islets, comparative experiments with rat islets were performed. In our hands, rat and mouse islets show identical responses, and, as observed with mouse islets (Fig. la) , TPA pretreatment of rat islets in normal TCM 199 medium leads to an abolition of both phases 1 and 2 of glucose-induced insulin secretion (results not shown). Thus no obvious species differences are involved. In view of the profound effect of Ca2" lowering in TCM 199 (Figs. la and 5), it seems likely that the observed deviations may rely on differences in the Ca2"-sensitivity of the islet preparations used or differences in the Ca2" concentration of the media used for TPA pretreatment. 
DISCUSSION
The results substantiate a role for protein kinase C in glucose-induced insulin secretion and suggest that protein kinase C may inhibit phase 1 and stimulate phase 2 of glucose-induced insulin secretion.
Previous observations with rat and mouse islets have demonstrated that TPA in the absence of stimulatory concentrations of glucose causes a slowly progressive increase in insulin secretion (Malaisse et al., 1980; Zawalich et al., 1983; Henquin et al., 1987) . A similar slow increase in insulin secretion in response to TPA was also observed in the present study. On the basis of this slow response to TPA, it has previously been suggested that protein kinase C is mainly involved in phase 2 of glucose-induced secretion (Zawalich et al., 1983) . In support of this hypothesis, early studies demonstrated that the non-specific protein kinase C inhibitor vitamin A (Taffet et al., 1983) showed a preferential inhibition of phase 2 of glucose-induced secretion (Chertow et al., 1979) . The present results substantiate a stimulatory role for protein kinase C in phase 2 of glucose-induced secretion. Thus both down-regulation of protein kinase C in RPMI 1640 or in TCM 199 supplemented with a,-adrenergic agonists or EGTA and direct inhibition of protein kinase C with staurosporine resulted in an inhibition of the progressively increasing phase 2 of glucose-induced insulin secretion.
It is accepted that glucose has the capacity to stimulate both phosphoinositide hydrolysis and diacylglycerol accumulation in islets (Best, 1986; Zawalich & Zawalich, 1988; Peter-Riesch et al., 1988) , and it has been demonstrated that glucose-induced phosphoinositide hydrolysis may parallel that biphasic pattern of insulin secretion (Zawalich & Zawalich, 1988) . Furthermore, several studies have shown that glucose in islets stimulates the release of arachidonic acid (Wolf et al., 1986) , a putative activator of several protein kinase C isoenzymes (Nishizuka, 1988) . However, recent observations in rat islets have cast doubt on the involvement of protein kinase C in glucose-induced secretion. It has been reported that down-regulation of protein kinase C does not affect glucose-induced insulin secretion (Hii et al., 1987; Metz, 1988) . Furthermore, the protein kinase C inhibitors clomiphene and H-7 did not inhibit glucoseinduced insulin secretion, but abolished TPA-induced secretion (Malaisse & Sener, 1985; Hughes & Ashcroft, 1988; Metz, 1988) . However, these results were obtained in static incubations, comprising both phases 1 and 2 of glucose-induced secretion. According to the present results, a stimulatory action of protein kinase C during phase 2 is counteracted by a major inhibitory effect of protein kinase C during phase 1 of glucose-induced insulin secretion, thus offering an explanation for the previous observed discrepancies.
At first glance, a concomitant inhibitory and stimulatory effect of protein kinase C may seem contradictory. However, previous studies have suggested that protein kinase C may have roles in the negative-feedback regulation of insulin secretion. Thus TPA has been found to attenuate vasopressin-stimulated phosphoinositide hydrolysis in RIN insulinoma cells (Monaco et al., 1988) . In line with similar observations in other tissues, this effect would decrease both InsP, -induced Ca2" mobilization from the endoplasmic reticulum and diacylglycerol activation of protein kinase C (Berridge, 1987) .
The exact locus for this feedback inhibition is not known and may involve receptors, G-proteins and phospholipase C. However, recent studies in mouse islets suggest that protein kinase C activity has the capacity to inhibit phosphoinositide-specific phospholipase C directly , suggesting that this effect of protein kinase C may comprise glucose-induced phosphoinositide hydrolysis as well. Furthermore, protein kinase C has been shown to stimulate the InsP3 5'-phosphomonoesterase in tissues (Connolly et al., 1986) , an effect which also would attenuate InsP3-induced Ca2" mobilization. Other evidence suggest that protein kinase C may activate the plasma-membrane-associated Ca2+/Mg2+-ATPase and stimulate Ca2" efflux from cells (Smallwood et al., 1988) . Accordingly, TPA has been found to decrease the K+-induced increase in cytosolic Ca21 in the clonal insulin-secreting RINm5F cell line (Arkhammar et al., 1986) and to stimulate Ca2' efflux from rat islets (Malaisse et al., 1980) . It is tempting to speculate that the efficacy of protein kinase C depletion to potentiate phase 1 of glucose-induced and carbamoylcholine-induced insulin secretion in part may reflect an abolition of these regulatory effects of protein kinase C on both phosphoinositide hydrolysis and Ca2+ fluxes.
The ability of both adrenaline and clonidine to preserve phase 1 of glucose-induced secretin during down-regulation of protein kinase C suggests that this effect is exerted through a2-adrenergic receptors. It is known that a2-adrenergic stimulation inhibits both glucose-induced and TPA-induced insulin secretion (Schuit & Pipeleers, 1986; Malaisse et al., 1980) . Surprisingly, however, neither adrenaline nor clonidine prevented a major loss in islet insulin content during TPA stimulation and down-regulation of protein kinase C (Table 5) . Although it is not believed that a2-adrenergic agonists inhibit phosphoinositide hydrolysis (Montague et al., 1985) , they have been shown to inhibit glucose-induced Ca21 influx (Wollheim et al., 1977) , cyclic AMP accumulation (Yamazaki et al., 1982) and glucose oxidation (Laychock, 1987) in islets. In addition, a direct inhibitory effect on Ca2+-induced exocytosis has been demonstrated in permeabilized islets (Tamagawa et al., 1985; Jones et al., 1987) and insulinoma cells (Ullrich & Wollheim, 1988 dition, the deviations may be explained by differences in the composition of the media used for TPA pretreatment, but the Ca2" concentrations in the media used in the previous studies were not specified. It has previously been demonstrated that carbamoylcholine stimulates phosphoinositide hydrolysis in islets (Best, 1986; Morgan et al., 1987) . In accordance, the present results substantiate a role for protein kinase C in carbamoylcholine-induced insulin secretion. Although carbamoylcholine does not stimulate insulin secretion in the absence of glucose (Trus et al., 1979) , carbamoylcholine at 3.3 mM-glucose was found to induce a biphasic type of secretion (Fig. 3) . In support of a stimulatory effect of protein kinase C during phase 2 of secretion, down-regulation ofprotein kinase C was found to abolish phase 2 ofcarbamoylcholine-induced secretion at 3.3 mMglucose. Furthermore, down-regulation abolished the potentiating effect of carbamoylcholine observable on addition during phase 2 of glucose (16.7 mM)-induced secretion. Finally, in line with the observations for glucose, protein kinase C also appears to have negative modulatory roles in phase 1 ofcarbamoylcholine-induced secretion, altogether suggestive of a common mechanism for these two secretagogues in stimulation of insulin secretion.
The mechanism by which protein kinase C potentiates phase 2 of glucose-induced and carbamoylcholineinduced insulin secretion is not known. We have recently suggested that protein kinase C may have a role in glucose and carbamoylcholine stimulation of cyclic AMP accumulation in islets , and most likely the potentiation of phase 2 of secretion involves an increased cyclic AMP accumulation. In contrast with TPA, however, cyclic AMP does not induce insulin secretion at non-stimulatory concentrations of glucose (Henquin, 1985) . It is possible that the potentiating effect of protein kinase C on insulin secretion may involve several different effects.
In conclusion, the present results have clearly demonstrated that protein kinase C inhibits phase 1 and stimulates phase 2 of glucose-induced insulin secretion. Both down-regulation of protein kinase C and direct inhibition of the kinase were found to potentiate phase 1 and inhibit phase 2 of glucose-induced secretion. The implication of protein kinase C in glucose-induced secretion is strengthened by similar effects of protein kinase C depletion on the two phases of carbamoylcholineinduced secretion, which are thought to involve protein kinase C activation. The mechanism of glucose in protein kinase C activation, as well as the mechanisms for protein kinase C in regulation of phases 1 and 2 of secretion, remain to be resolved. It is suggested that the regulation by protein kinase C comprises both an attenuating effect on phosphoinositide hydrolysis and Ca2" mobilization and an amplifying effect on cyclic AMP accumulation in response to glucose.
